Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents

NCT04954287 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

BIOLOGICAL: CVXGA1 low dose
BIOLOGICAL: CVXGA1 high dose

Sponsor

CyanVac LLC